LifeSciVC

JANUARY 3, 2024

Recognizing the therapeutic potential of effectively disrupting the CBM complex in the NF-kB pathway, using our technology, we have developed small molecules that we believe to be the first and only inhibitors of MALT1’s scaffolding function. The post Signaling Complexes: A Ripe Opportunity for Drug Development appeared first on LifeSciVC.

Drug Development 96

Drug Development Drugs Small Molecule Disease 96

Drug Patent Watch

DECEMBER 9, 2024

This approach has led to the discovery of numerous potential drug candidates. From Lab to Market: The Long Road of Drug Development Once a promising compound is identified, it enters the long and costly process of drug development. Q: How long does a drug patent last?

Drugs 97

Drugs Drug Development Pharmaceuticals Production 97

Conversations in Drug Development Trends

MAY 30, 2024

This trend is on the rise despite recent disappointments with clinical trial outcomes, which have the potential to destabilize the industry in the short term regarding drug development strategy and optimal study designs. The shared placebo design is another approach to accelerating drug development in ALS research.

Treatment 81

Treatment Clinical Trials Small Molecule Therapies 81

BioPharma Drive: Drug Pricing

SEPTEMBER 16, 2024

Applying CAR T-cell therapy in new clinical settings presents unique challenges. Worldwide Clinical Trials is at the forefront, partnering with drug development teams to map this new path forward.

Therapies 130

Therapies Trials Clinical Trials Drug Development 130

Drug Target Review

MARCH 24, 2025

Promising areas for AI implementation When discussing the most transformative AI applications in drug discovery, Sujeegar identifies a particularly ambitious goal: developing AI models that can simulate human pharmacokinetics and pharmacodynamics (PK/PD) using only preliminary laboratory data.

Clinical Trials 59

Clinical Trials Animal Testing Drugs Pharmacokinetics 59

FDA Law Blog: Drug Discovery

NOVEMBER 10, 2024

Background on the Grants Program Launched as part of the Orphan Drug Act of 1983, this program aims to encourage research and development of drugs, biologics, medical devices, and medical foods for rare diseases, defined as conditions that affect fewer than 200,000 people in the U.S.

Clinical Development 69

Clinical Development Production Clinical Trials Treatment 69

Covalent Modifiers

DECEMBER 23, 2023

3c01502 Enzyme inhibitors that form covalent bonds with their targets are being increasingly pursued in drug development. This overview seeks to inform best practices for developing new covalent inhibitors and highlight appropriate steps to address gaps in knowledge presently limiting assay reliability and reproducibility.

Drug Development 147

Drug Development Drugs 147

Drug Target Review

AUGUST 7, 2024

The pharmaceutical industry is undergoing a major shift towards the development of breakthrough medicines and advanced therapies. This continued innovation highlights the complexity of the drug development process, particularly as the field is highly regulated by health authorities around the world.

Drug Development 59

Drug Development Clinical Pharmacology Clinical Trials Drugs 59

Drug Patent Watch

DECEMBER 17, 2024

Today, they’re strategic partners in drug development and manufacturing, offering end-to-end solutions that can make or break a pharmaceutical company’s success. This shift reflects the increasing complexity of drug development and the need for specialized expertise at every stage of the process.

Pharmaceuticals 90

Pharmaceuticals Therapies Production Pharmaceutical Companies 90

DrugBaron

JULY 19, 2022

Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules.

Small Molecule 100

Small Molecule Drugs DNA Pharma Companies 100

LifeSciVC

FEBRUARY 27, 2024

By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC Patients and their care partners are at the center of our work in the life sciences industry – but at what point during the drug development process should companies start to engage these key stakeholders?

Drug Development 64

Drug Development Disease Drugs Treatment 64

Alta Sciences

NOVEMBER 20, 2024

Now Available Online — Scientific Posters Presented at Eurotox 2024!

Therapies 40

Therapies Drug Development Research Drugs 40

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

The Premier Consulting Blog

JULY 31, 2024

In this blog, we explain the role of clinical pharmacology in drug development and demonstrate how the right strategy can accelerate development under the US Food and Drug Administration (FDA) 505(b)(1) and 505(b)(2) New Drug Application (NDA) pathways.

Clinical Pharmacology 52

Clinical Pharmacology Drug Development Pharmacokinetics Drugs 52

Alta Sciences

NOVEMBER 15, 2024

4 Essential Topics to Cover in Your First CRO Meeting pmjackson Fri, 11/15/2024 - 19:22 Starting a partnership with a contract research organization (CRO) is a sometimes intimidating—yet exciting—first step in your drug development journey.

Drug Development 52

Drug Development Clinical Trials Trials Drugs 52

PPD

OCTOBER 17, 2024

This expansion represents a significant opportunity for both drug developers and patients, while also presenting a new and diverse set of challenges for drug developers, particularly in clinical trial execution. Factoring in cultural dynamics is key to enabling new therapy treatment success.

Therapies 97

Therapies Clinical Trials Clinical Research Trials 97

Perficient: Drug Development

NOVEMBER 20, 2024

Collaborate Across Sectors : Governments, businesses, and tech leaders must work together to develop secure, quantum-resilient systems. Conclusion Quantum computing holds incredible promise but also presents unprecedented risks, particularly to cybersecurity.

Government 106

Government Compliance Research 106

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. Part of the challenge is that patients present with very different kinds of clinical phenotypes, meaning the populations are heterogeneous.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Drug Target Review

JANUARY 15, 2024

An important limitation of antibodies against tumour antigens is that these agents direct responses to molecular targets present on the surface of the cell. Figure 1: HLA Class I presentation of peptides derived from intracellular antigens. As described below, it also presents challenges and opportunities for TCR-based therapeutics.

Engineering 110

Engineering DNA Virus Immune Response 110

Codon

NOVEMBER 3, 2024

As an undergraduate biology student, I spent some time in a TB lab working on antibiotic resistance — a growing concern for drug developers. tuberculosis ’ cellular architecture, however, presents an additional challenge for scientists developing new antibiotics. tuberculosis. However, hope prevails.

Vaccine 96

Vaccine Trials Therapies Treatment 96

Chemical Biology and Drug Design

SEPTEMBER 12, 2023

Preliminary therapeutics becoming ineffective that might lead to noteworthy mortality presents a crucial challenge for the scientific community. In the drug development process, linker hybrids acquire the top position due to their excellent π-stacking and Van der Waals interaction with the DNA active sites of pathogens.

DNA 100

DNA Drug Development Drugs 100

Drug Target Review

DECEMBER 16, 2024

Dr Pooja Hingorani, Senior Medical Director of Oncology Early Development at AbbVie , shares her journey in STEM, from her early days in New Delhi to her impactful career in oncology research and drug development. Opportunities in clinical research and drug development were not always easy to come by.

Medical Schools 52

Medical Schools Clinical Research Drug Development Trials 52

Drug Target Review

AUGUST 28, 2024

This is reflected in the MATCH data recently presented at the European Association for the Study of the Liver (EASL), where two patients in the control group had a liver transplant and seven patients died, whereas there were no liver transplants and only two deaths in the treated group.

Therapies 116

Therapies Disease Engineering Medical Schools 116

PPD

JULY 29, 2024

In today’s data-driven world, AI has become valuable and indispensable, enabling organizations to extract valuable insights from vast amounts of data, make informed decisions and drive innovation across different sectors — including drug development.

Clinical Research 98

Clinical Research Clinical Trials Research Trials 98

DrugBank

JULY 20, 2023

Rare diseases, therefore, present compelling opportunities for Drug Development. Since each disease is present in small groups of patients, this research is also fraught with complex challenges. This new resource for rare disease research will be integral to our overall drug development solution.

Disease 98

Disease Clinical Trials Trials FDA 98

Drug Target Review

DECEMBER 23, 2024

Antibody-drugconjugates (ADCs) represent a significant advancement in drug discovery, combining the precision of monoclonal antibodies with the cancer-killing power of cytotoxic drugs. This type of analysis is crucial for drug developers, providing a framework to identify and mitigate toxicity risks early in the design process.

Research 52

Research Treatment Therapies Drug Development 52

Drug Target Review

OCTOBER 2, 2023

Immunopeptidomics is a rapidly expanding field at the intersection of immunology and proteomics that focuses on the identification and characterization of peptides presented by major histocompatibility complex (MHC) molecules, also known as the human leukocyte antigen (HLA), on cell surfaces. Research Square. 2023 [cited 2023 Sep 21].

Immune Response 105

Immune Response Vaccine Disease Research 105

Conversations in Drug Development Trends

MAY 10, 2024

I am looking forward to presenting on “Designing a Psychedelic Clinical Trial for Borderline Personality Disorder” at 11:15 AM on Thursday, May 23.

Clinical Trials 95

Clinical Trials Trials Treatment Drug Development 95

Conversations in Drug Development Trends

NOVEMBER 12, 2024

Cell therapy can be effective, but clinically testing the treatment presents several logistical challenges that require early planning and rigorous management by specialized and experienced teams throughout the clinical trial timeline.

Therapies 72

Therapies Clinical Supply Clinical Trials Trials 72

Conversations in Drug Development Trends

JANUARY 24, 2024

Much of what we discuss I covered in my presentation, “Leveraging Genetics to Support Rare Disease Clinical Trials,” at last year’s World Orphan Drug Congress (WODC) EU. One diagnostic example that I discussed in my presentation is autism. Enrolling adequate populations will be required to advance these programs.

Trials 75

Trials Disease Clinical Trials Clinical Research 75

Drug Target Review

APRIL 7, 2025

GPCRs are critical targets for drug development due to their involvement in numerous disease pathologies, with many medications working by either activating or inhibiting these receptors. 2022) Why 90% of clinical drug development fails and how to improve it?, References Sun D, et al. doi:10.1016/j.apsb.2022.02.002.

Fragment Screening 52

Fragment Screening Drugs Small Molecule Biophysical Assays 52

Drug Target Review

SEPTEMBER 22, 2023

5 Organoids are recognised as New Alternative Methods (NAMs) in drug development. This recognition was codified by the United States Food and Drug Administration (FDA) in 2022 with the signing of the FDA Modernisation Act 2.0 This can aid in the development of safer, more effective therapeutic strategies. Front Genet.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

FDA Law Blog: Drug Discovery

JANUARY 30, 2025

They also present a more intense focus on the timelines for confirmatory study initiation and completion as well as the feasibility of those studies to verify clinical benefit within those timelines.

FDA 105

FDA Trials Disease Drugs 105

KIF1A

JANUARY 13, 2024

Aditi Falnikar’s presentation from our 2023 KAND Conference Read the Article Rare Roundup FDA issues final guidance on rare disease drug development As we continue to explore new therapeutic avenues for treating KAND, it is crucial to think about the regulatory steps those therapies will face.

DNA 105

DNA Regulations Drug Development Disease 105

Drug Target Review

SEPTEMBER 25, 2024

5 Here, the original oncogene is still present but the transdifferentiated cancer cells are less dependent on it. Investigating non-oncogene resistance as a parallel defense mechanism used by cancer cells to evade therapies could therefore present a significant opportunity to address drug resistance more comprehensively.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

Drug Target Review

NOVEMBER 29, 2023

By doing this, we ensure we are well-positioned to take advantage of the latest findings and technologies that can help propel our research and development efforts forward, with the ultimate goal of delivering the right medicine to the right patient as quickly as we can. Sifis: Thank you, Michelle!

Engineering 111

Engineering Drug Development Disease Research 111

DrugBank

JUNE 27, 2024

Research infrastructure also presents hurdles. Additionally, integrating diverse data types is a high demand task , and obtaining generic active ingredients can be challenging, especially if the drug is no longer commercially available.

Drugs 98

Drugs Pharma Companies Clinical Trials Computational Chemistry 98